Share →
    • robert mosier

      Robert Mosier

      July 27, 10 AM Pacific, 1 PM Eastern:

      An Update on Risperdal litigation

with presenter Robert Mosier of The Sanders Firm in Los Angeles. His practice is focused on representing plaintiffs harmed by large pharmaceutical and medical devices.

About our presenter

Robert A. Mosier, represents plaintiffs in a variety of medical malpractice, mass tort, pharmaceutical and medical device matters. Rob began his practice as an attorney at a prestigious medical malpractice defense firm where he defended physicians, hospitals and nursing homes accused of malpractice. He then left the defense practice in 1999 to focus on representing victims of doctor, hospital, drug and medical device manufacturer negligence, including victims of brain and birth injury, nursing home abuse, catastrophic injury as well as wrongful death, and has tried numerous cases in these areas.

Rob is licensed to practice law in Arizona and California, and is admitted to practice before the United States Supreme Court, Federal Ninth District Court of Appeal and Federal Ninth Circuit Court.

He earned his Bachelor’s degree in Law and his Juris Doctorate degree from Thomas Jefferson School of Law.

  • Member of the American Bar Association
  • Member of the Arizona Trial Lawyers Association
  • Board of Directors for the Orange County Trial Lawyers Association
  • Member of the Million Dollar Advocates Forum, The Top Trial Lawyers in
    America; membership limited to attorneys who have won million and multi-
    million dollar verdicts and settlements.
  • Received AV-rating from Martindale-Hubbell; the highest rating offered by this
    national attorney rating organization.


register now NTL webinarRisperdal (risperidone) is an atypical (with different chemical reactions in the brain than older antipsychotics) antipsychotic used to treat adult schizophrenia, adolescent schizophrenia, schizoaffective disorder, the mixed and manic states associated with bipolar disorder (alone or in combination with valproate or lithium), and irritability in children with autism.

Risperdal has also been used off-label [use not approved by the US Food and Drug Administration] for the treatment of obsessive-compulsive disorder, severe, treatment-resistant depression, other anxiety disorders, Tourette syndrome, eating disorders, and disruptive behavior disorders in children, among others.

Risperdal carries a black box warning asserting that it is not approved for use in elderly patients with dementia-related psychosis because of an increased risk of death. Major warnings regarding the use of Risperdal include:

  • a risk of causing Neuroleptic Malignant Syndrome
  • a potential to cause tardive dyskinesia
  • the dosage should be reduced for elderly patients and patients with liver or kidney disease
  • patients with diabetes or risk factors for diabetes should have regular blood glucose monitoring, all others should be monitored for symptoms of hyperglycemia
  • patients should not breast-feed and should notify their doctor if pregnant or planning to become pregnant
  • combining with blood pressure medicine can result in blood pressure that is too low

In July 2009, the FDA announced the approval of labeling changes to the Precautions section for Risperdal, including:

  • There have been reported events of leukopenia/neutropenia and agranulocytosis in clinical trials and/or postmarketing experience.
  • Possible risk factors for leukopenia/neutropenia may include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with these predispositions should have their complete blood count monitored frequently during the first few months of therapy. Discontinuation of Risperdal should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
  • Patients with clinically significant neutropenia should be carefully monitored for fever or other signs or symptoms of infection and treated promptly if such signs or symptoms occur. Patients with severe neutropenia should discontinue Risperdal and have their WBC monitored until recovery.